These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
832 related articles for article (PubMed ID: 33276387)
1. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. Sader HS; Carvalhaes CG; Arends SJR; Castanheira M; Mendes RE J Antimicrob Chemother; 2021 Feb; 76(3):659-666. PubMed ID: 33276387 [TBL] [Abstract][Full Text] [Related]
2. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022). Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826 [TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020). Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Castanheira M Eur J Clin Microbiol Infect Dis; 2022 Mar; 41(3):477-487. PubMed ID: 35041100 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021. Wise MG; Karlowsky JA; Mohamed N; Kamat S; Sahm DF Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1135-1143. PubMed ID: 37526796 [TBL] [Abstract][Full Text] [Related]
6. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018). Piérard D; Stone GG BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341 [TBL] [Abstract][Full Text] [Related]
7. Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21). Sader HS; Castanheira M; Kimbrough JH; Kantro V; Mendes RE JAC Antimicrob Resist; 2023 Apr; 5(2):dlad032. PubMed ID: 36968952 [TBL] [Abstract][Full Text] [Related]
8. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values. Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017). Ko WC; Stone GG Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155 [TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19). Sader HS; Mendes RE; Duncan LR; Carvalhaes CG; Castanheria M J Antimicrob Chemother; 2022 Sep; 77(10):2642-2649. PubMed ID: 35897129 [TBL] [Abstract][Full Text] [Related]
11. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020). Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of aztreonam-avibactam against metallo-β-lactamase-producing Enterobacteriaceae-A multicenter study in China. Zhang B; Zhu Z; Jia W; Qu F; Huang B; Shan B; Yu H; Tang Y; Chen L; Du H Int J Infect Dis; 2020 Aug; 97():11-18. PubMed ID: 32473388 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of ceftazidime/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017. Stone GG; Ponce-de-Leon A J Antimicrob Chemother; 2020 Jul; 75(7):1859-1873. PubMed ID: 32277820 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018. Kiratisin P; Kazmierczak K; Stone GG J Glob Antimicrob Resist; 2021 Dec; 27():132-141. PubMed ID: 34478880 [TBL] [Abstract][Full Text] [Related]
17. Assessment of broth disk elution method for aztreonam in combination with ceftazidime/avibactam against Song P; Xu J; Jiang L; Zhang Q; Liu C Microbiol Spectr; 2024 Oct; 12(10):e0095324. PubMed ID: 39225487 [TBL] [Abstract][Full Text] [Related]
19. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula. Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488 [TBL] [Abstract][Full Text] [Related]
20. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Bhatnagar A; Boyd S; Sabour S; Bodnar J; Nazarian E; Peinovich N; Wagner C; Craft B; Snippes Vagnone P; Simpson J; Stone VN; Therrien M; Bateman A; Lower D; Huang JY; Gumbis S; Lonsway D; Lutgring JD; Karlsson M; Brown AC Antimicrob Agents Chemother; 2021 Jul; 65(8):e0048621. PubMed ID: 34060895 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]